UNSPSC 51391737: Ritodrine

This classification denotes a beta-adrenergic agonist, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier I0Q6O6740J. European Medicines Agency schedules Ritodrine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10340MIG. Ritodrine generally arises in the molecular formula C17H21NO3.

UNSPSC 51391737 Ritodrine is a Commodity code that in recent state and local procurement activity covers pharmaceutical products and drug-related supplies procured by health and human services agencies. The recent opportunities tagged to this code, however, show substantial mismatch with the code's nominal scope—Ritodrine is a specific tocolytic medication used in obstetric practice, yet the opportunities posted under it are soliciting naloxone (an opioid antagonist), safe drug deactivation systems, and direct-to-manufacturer prescription fulfillment capabilities. The code shows minimal relevant recent activity aligned with its stated product category. State and local issuing bodies soliciting under this code include county health departments and state health and human services commissions, though the narrow recent sample reflects exploratory and procurement-stage activity rather than mature buying patterns.

Geographic activity centers on Florida and Texas based on the available opportunities. Seminole County, Florida issued an IFB (IFB60459723LAS, posted June 30, 2026, due July 26, 2023) seeking annual procurement of 1,900 units of naloxone and 800 safe drug deactivation systems with quarterly deliveries to the county's community health building; the contract includes a two-year initial term with one-year renewal option and requires E-Verify compliance and standard commercial insurance. The Texas Health and Human Services Commission posted a Request for Information (HHS0017013, posted April 3, 2026, due April 3, 2026) to explore vendor capacity for direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager arrangements. The mismatch between the code's pharmaceutical name and the actual products being procured suggests either misclassification in the source data or a broadened interpretation of the code in practice; business development professionals should verify whether opportunities genuinely fall under UNSPSC 51391737 before investing pursuit resources.